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Exoenzyme S (ExoS) is translocated into eukaryotic cells by the type III secretory process and has been
hypothesized to function in conjunction with other virulence factors in the pathogenesis of Pseudomonas
aeruginosa. To gain further understanding of how ExoS might contribute to P. aeruginosa survival and
virulence, ExoS expression and the structural gene sequence were determined in P. aeruginosa soil isolates and
compared with ExoS of clinical isolates. Significantly higher levels of ExoS ADP-ribosyltransferase (ADPRT)
activity were detected in culture supernatants of soil isolates compared to those of clinical isolates. The higher
levels of ADPRT activity of soil isolates reflected both the increased production of ExoS and the production of
ExoS having a higher specific activity. ExoS structural gene sequence comparisons found the gene to be highly
conserved among soil and clinical isolates, with the greatest number of nonsynonymous substitutions occurring
within the region of ExoS encoding GAP function. The lack of amino acid changes in the ADPRT region in
association with a higher specific activity implies that other factors produced by P. aeruginosa or residues
outside the ADPRT region are affecting ExoS ADPRT activity. The data are consistent with ExoS being integral
to P. aeruginosa survival in the soil and suggest that, in the transition of P. aeruginosa from the soil to certain
clinical settings, the loss of ExoS expression is favored.
Pseudomonas aeruginosa is an opportunistic pathogen that
can produce severe infections or death when the person af-
fected has a compromised immune system or severe tissue
damage (2). While P. aeruginosa can readily adapt to growth
within a human host if allowed access, its primary residence is
within the environment, where it can be found in a number of
habitats, including soil, water, plant and animal surfaces, and
decaying organic matter (3, 31, 53, 55, 63). Although the pre-
cise ecological niche of P. aeruginosa is unknown, it likely
functions, along with other pseudomonads, in decomposition
and environmental recycling within the soil (21, 55, 57). Fac-
tors that contribute to the virulence of P. aeruginosa in the
human host, such as adhesins, invasins, and resistance to des-
iccation, are the same as those that contribute to its adaptabil-
ity in the environment.
Exoenzyme S (ExoS) has been implicated as a virulence
factor of P. aeruginosa; however, its precise role in the patho-
genicity of this organism remains unknown. ExoS is directly
translocated into eukaryotic cells by the contact-dependent
type III secretory process (61) and, as such, it provides the
bacterium with a mechanism for manipulating the eukaryotic
cells it encounters. In support of ExoS contributing to P.
aeruginosa pathogenicity, bacterial translocation of ExoS into
epithelial cells results in a general inactivation of cellular func-
tion, as recognized by the inhibition of DNA synthesis, loss of
focal adhesion, cell rounding, and microvillus effacement (46).
ExoS cellular toxicity has also been found to parallel the op-
portunistic nature of P. aeruginosa infections, with compro-
mised epithelial cell monolayers being more sensitive to the
effects of bacterially translocated ExoS than healthy confluent,
polarized monolayers (12, 40). While the mechanism of action
of ExoS leading to altered cell function is only partially under-
stood, the evidence supports the view that both its amino-
terminal GTPase-activating (GAP) activity (19) and carboxy-
terminal ADP-ribosyltransferase (ADPRT) activity (30)
contribute to these effects (17, 19, 39, 59). Notably, the AD-
PRT activity of ExoS has a strict requirement for a eukaryotic
protein cofactor, 14-3-3 proteins (7), emphasizing a functional
link between this activity and eukaryotic cells. The ability of
ExoS to inactivate eukaryotic cell function, combined with its
preferential toxicity for compromised epithelial cells, is consis-
tent with ExoS providing the bacterium with a means of selec-
tively targeting and interfering with the function of eukaryotic
cells it encounters.
While an extensive number of studies have been performed
to determine the contribution of ExoS to P. aeruginosa viru-
lence in clinical settings, the role of ExoS in the survival of P.
aeruginosa in the environment remains relatively unexplored.
Our studies have focused on examining the role of ExoS in the
fitness of P. aeruginosa in its natural environmental habitat,
with the notion that this might provide insight into the function
of ExoS in the P. aeruginosa infectious process. To assess the
relevance of ExoS production to P. aeruginosa survival in the
environment, we analyzed P. aeruginosa soil isolates for the
production of ExoS and then compared both ExoS production
and the exoS gene sequence of soil and clinical isolates. We
detected the exoS gene in all soil isolates examined, a finding
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which is consistent with the exoS gene being more prevalent in
P. aeruginosa within the soil than previously reported for clin-
ical isolates (11). While the exoS gene sequence of soil and
clinical isolates was found to be highly conserved, the ExoS
ADPRT activity was significantly higher in culture superna-
tants of soil isolates compared to clinical isolates. The data
support the idea that ExoS production is favored in P. aerugi-
nosa soil isolates and, as such, may be more integral to P.
aeruginosa survival in soil than in certain clinical habitats.
MATERIALS AND METHODS
Soil collection and P. aeruginosa isolation. Eight of the soil isolates examined
in this study were obtained using a standard soil probe from soil samples taken
from random locations throughout Horry and Georgetown Counties in South
Carolina. Isolates were obtained by laying out 6-m transects across each location,
and five samples that were 15-cm deep were taken at 1-m intervals across the
transect. The samples were bulked in zip-lock bags and held on ice until pro-
cessing. Following collection, the soil samples were processed as outlined by
Green et al. (21). Fifty grams of each soil sample was placed in a flask containing
100 ml of sterile distilled water. The contents were shaken for 1 h at 300 rpm in
a water bath at room temperature. A 0.5-ml aliquot of the soil solution was added
to a capped tube with 4.5 ml of sterile salts plus acetamide (SA) broth (5 g of
NaCl, 0.2 g of MgSO4, 1 g of NH4H2PO4, 1 g of K2HPO4, and 20 g of acetamide
[Sigma Chemical Co., St. Louis, Mo.] per 1 liter of distilled H2O) (22, 54) and
incubated without shaking at 42°C for 24 to 48 h. A 0.1-ml aliquot of this culture
was spread on plates of King’s B plus cetrimide (hexadecyltrimethylammonium
bromide; Sigma) (KBC) medium (4, 29) and incubated for 24 to 48 h at 42°C.
Bacterial colonies that were fluorescent on KBC plates were streaked on plates
of King’s A medium (29) to check for pyocyanin production. Isolates that pro-
duced both fluorescein and pyocyanin, grew at 42°C, and had an odor charac-
teristic of P. aeruginosa were subsequently verified as P. aeruginosa based on
biochemical characteristics by the Clinical Microbiology Laboratory at the Med-
ical University of South Carolina, Charleston. Two additional P. aeruginosa soil
isolates, U1 and U3, were isolated from a creosote-contaminated site in
Fairhope, Ala., and were provided by Pamela Morris.
Bacterial strains and growth conditions. The following clinical P. aeruginosa
isolates were used in this study: strain 388, a burn wound isolate (1), and its
derivatives 388DS and 388DT (33, 60) were provided by Dara Frank; PA01, a
wound isolate (24); DG1, a cystic fibrosis (CF) lung isolate (5); PA103, a sputum
isolate (38); FRD1 (45), its derivative, FRD2 (20), DO62, and DO249 are CF
isolates provided by Dennis Ohman; strain ATCC 27853 is a blood isolate
obtained from the American Type Culture Collection (ATCC); strain WR5 (49)
was provided by Barbara lglewski; and PAK (ATCC 25102) is included among
the clinical isolates, although its origin is uncertain. Soil isolates examined in this
study include CCU1 to CCU6, CCU8, CCU9, U1, and U3. Stock cultures of all
strains were maintained in 10% sterile skim milk at 270°C. For short-term
laboratory maintenance, cultures were maintained on Luria-Bertani (LB) agar
plates and stored at 4°C. To induce ExoS production in vitro, bacteria were
cultured for 18 h at 37°C in a chelated dialysate of Trypticase soy broth supple-
mented with 10 mM nitrilotriacetic acid (Sigma), 1% glycerol, and 100 mM
monosodium glutamate (TSBD-N) medium (27, 34). The optical density at 590
nm (OD590) of cultures was determined at 18 h to compare the growth rates of
the bacterial strains.
Measurement of ExoS enzyme activity. ExoS ADPRT activity was assayed and
distinguished from that of exotoxin A (ETA) using a defined assay system which
measured the incorporation of radiolabeled ADP-ribose into the artificial sub-
strate soybean trypsin inhibitor (SBTI; Sigma) as previously described (34). In
these analyses, each 40-ml reaction mixture contained 0.2 M sodium acetate (pH
6.0), 1 mM nicotinamide [U-14C]adenine dinucleotide (252 Ci/mol; Amersham
Life Sciences, Arlington Heights, Ill.), 100 mM SBTI, a 40 nM concentration of
the 14-3-3j, co-factor (Upstate Biotechnology, Inc., Lake Placid, N.Y.), and 10 ml
of culture supernatant, diluted as indicated. The reaction mixtures were incu-
bated at 25°C for 30 or 40 min and stopped by the addition of 40 ml of ice-cold
20% trichloroacetic acid (TCA). The mixture was then spotted on 0.45-mm-pore-
size HA filters (Millipore, Bedford, Mass.) on a vacuum manifold, washed twice
with 5% TCA and once with ethanol, and dried. The incorporation of radiolabel
was determined by scintillation counting and quantified as picomoles or femto-
moles of ADP-ribose transferred per minute to SBTI per supernatant volume.
The ExoS ADPRT activity of each isolate was calculated relative to the slope of
the dilution curve within the linear range of the ADPRT assay. To relate ExoS
ADPRT activity to total protein secretion, protein concentrations in culture
supernatants were determined based on densitometry analysis of 10 ml of culture
supernatant resolved on sodium dodecyl sulfate (SDS)–10% polyacrylamide gel
electrophoresis (PAGE) gels and stained with Coomassie blue. This method of
analysis both allowed a visualization of culture supernatant proteins and circum-
vented high background protein levels associated with bacterial medium. The
specific activity of ExoS of each isolate was calculated as the ratio of ExoS
ADPRT activity to ExoS protein concentrations in culture supernatants, the
latter being determined based on immunoblot analyses (described below). Sta-
tistical analyses of quantified ExoS activity levels were performed using Sigma
Stat Statistical Software version 2.0 and the indicated test.
Immunoblot analysis of ExoS in culture supernatants and cell extracts. Cul-
ture supernatants of P. aeruginosa growth in ExoS induction media were resolved
on SDS–7.5% PAGE gels using the method of Laemmli (36). Immunoblots were
performed according to the method of Towbin et al. (58) by transferring the
resolved culture supernatants to polyvinylidene difluoride membranes (Milli-
pore) and probing them with antisera, produced using previously described
methods (47), against either native ExoS or ExoS reduced and denatured with
5% b-mercaptoethanol and 8 M urea, respectively, gel purified from strain DG1.
Immunoblots were developed using a peroxidase-conjugated goat anti-rat im-
munoglobulin G (IgG; Sigma) and visualized by enhanced chemiluminescence
(ECL; Amersham). Quantification of ExoS was performed on immunoblot im-
ages within the linear concentration range, and densitometry values were ob-
tained using the NIH image version 1.6 program and related to a previously
quantified ExoS standard.
Genomic DNA purification and amplification of the exoS structural gene.
DNA was purified from overnight Luria broth cultures of P. aeruginosa strains
using the salting-out procedure (41) of the PureGene DNA isolation kit (Gentra
Systems, Inc., Minneapolis, Minn.) according to manufacturer’s specifications for
purifying DNA from gram-negative bacteria. Two sets of PCR primers, synthe-
sized at the DNA synthesis facility at the Medical University of South Carolina,
were used to isolate the exoS gene from P. aeruginosa genomic DNA. Primer set
1 consisted of the following: (upper) 59-GTCAGCATATGCATATTCAATCGC
T-39, which included an NdeI restriction site (underlined), with the ATG start
site of ExoS indicated in boldface, and (lower) 59-CGAACCGAATTCTCAGG
CCAGATCA-39, which included an EcoRI site (underlined), with the TGA stop
codon of ExoS in boldface. Primer Set 2 consisted of: (upper) 59-GTCAGCAT
ATGCATATTCAATCGCTTCAGCAG-39, which extended beyond the upper
primer of set 1, and (lower) 59-GCATGGATCCGCTGCCGAGCCAAGAATC-
39, which is downstream of the exoS structural gene of strain 388 and includes a
BamHI site (underlined). PCRs were performed using a GeneAmp PCR System
9700 machine (PE Applied Biosystems, Foster City, Calif.). Each 50-ml reaction
mixture contained 29.5 ml of distilled water, 10 ml of a 53 buffer solution
containing 1.7 mM MgCl2 (Gibco-BRL, Gaithersburg, Md.), 1 ml of each primer
(25 mM), 1 ml of each deoxynucleoside triphosphate (10 mM; Gibco-BRL), 2.5 ml
of dimethyl sulfoxide (Sigma), 1 ml of genomic DNA (100 ng/ml), and 1 ml of
Elongase Enzyme Mix (Gibco-BRL). The Elongase Mix contains Taq polymer-
ase and the proofreading Pyrococcus sp. strain GB-D polymerase and was used
to reduce the possibility of sequence errors in the PCR amplification of ExoS.
The polymerase Elongase was added after 5 min at 98°C as a “hot start.” The
PCR temperature cycles differed for the two primer sets. The cycle for primer set
1 was as follows: 98°C (5 min); 80°C (2 min); 20 cycles of 94°C (30 s), 60°C (30
s, ramped down 0.5°C lower each cycle, to an endpoint of 50°C), and 68°C (90 s);
and then 20 cycles of 94°C (30 s), 50°C (30 s), and 68°C (90 s). The cycle for
primer set 2 was as follows: 98°(5 min); 80°(2 min); 16 cycles of 94°C (30 s), 68°C
(30 s ramped downed down 0.5°C lower every cycle, to an endpoint of 60°C), and
68°C (90 s); and then 24 cycles of 94°C (30 s), 60°C (30 s), and 68°C (90 s).
Preparation of exoS PCR products for sequencing. exoS PCR products were
purified by excising the appropriate sized band from 1% agarose gels, following
electrophoresis using TAE buffer (40 mM Tris-acetate, 1 mM EDTA; pH 8.0) for
approximately 30 min at 100 V. The DNA was extracted from the agarose gel
slices using a GeneClean kit, a silica-based DNA purification procedure (Bio
101, Vista, Calif.), according to the manufacturer’s specifications. The exoS PCR
products were sequenced directly without cloning at the DNA sequencing facility
at the Medical University of South Carolina using an ABI 377 automated DNA
sequencer.
Sequence comparison. Computer manipulations of sequence data were per-
formed using the BLAST programs available at the National Center for Bio-
technology Information website (http://www.ncbi.nlm.nih.gov) and, for multiple
sequence alignments, CLUSTALW 1.8, available at Baylor College of Medicine’s
Search Launcher Web Site (http://searchlauncher.bcm.tmc.edu/searchlauncher).
Nucleotide sequences were aligned using the PileUp program of the Wisconsin
Package of sequence analysis programs (GCG version 10; Madison, Wis.). The
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mean number of synonymous nucleotide substitutions per potential synonymous
site (dS), the mean number of nonsynonymous substitutions per potential non-
synonymous site (dN), and their variances were estimated from all pairwise
comparisons of the sequences being analyzed by using established methods (42,
43). These nucleotide distances (proportion of nucleotide differences) were used
to determine the form of natural selection operating at the protein level, where
dS . dN indicates purifying selection (selection against amino acid changes) and
dN . dS indicates positive selection (selection for amino acid changes) (25). The
null hypothesis of no difference between dS and dN was tested using a two-tailed
Z test (44). Evolutionary trees were constructed using the neighbor-joining
method (52). When nucleotide distances between sequences corrected for mul-
tiple substitutions at a site (28) were #0.05, as for exoS sequences, the neighbor-
joining method was applied to the distances. When nucleotide distances were
much greater, such that dS was greater than 0.5, indicating the saturation of
synonymous sites, as in the case of distances between the ExoT sequence and the
ExoS sequences, the neighbor-joining method was applied to amino acid dis-
tances (proportion of amino acid differences) between sequences (44). The level
of confidence in internal branches of a tree (those separating clusters of se-
quences) was determined by running 1,000 bootstrap pseudoreplicates (44).
Branch lengths of the ExoS tree in terms of the number of synonymous nucle-
otide substitutions per potential synonymous site (bS) and the number of non-
synonymous substitutions per potential nonsynonymous site (bN) were estimated
from proportional synonymous (pS) and nonsynonymous (pN) distances between
pairs of sequences (42) using Rzhetsky and Nei’s (51) method of computing
branch lengths (64).
RESULTS
Soil survey. A survey for the presence of P. aeruginosa in
soils was conducted as part of an undergraduate research
project (23). Approximately 16% of soils surveyed were posi-
tive for P. aeruginosa. These soils were predominantly sandy
and acidic in nature, but individual soils were variable with
respect to both percent sand fraction and pH. Nine isolates
from this survey were obtained for further study and labeled
CCU1 to CCU9. Culture CCU7 was lost early in the process
and does not appear in these studies. The phenotypic charac-
teristics of these soil isolates when grown under identical con-
ditions were consistent with each isolate being different. Two
other P. aeruginosa strains, U1 and U3, isolated from a differ-
ent geographical region, were introduced into the study at a
later time to evaluate whether the findings on ExoS production
extended to a more distant geographical location.
Analyses of ExoS production by environmental isolates. Pre-
liminary assays of soil isolates, CCU1 to CCU9, grown under
ExoS induction conditions, found all but one strain, CCU1, to
produce ExoS ADPRT activity in culture supernatants (Fig. 1).
Further examination of the supernatants by immunoblot anal-
yses using antibodies produced either against the native or the
reduced-denatured form of ExoS detected variation in the
amount of ExoS produced by the individual soil isolates (Fig.
2A). Variation was also detected in the levels of ExoS of the
clinical strains, which were produced and analyzed in parallel
for comparison. The antiserum produced against the native
form of ExoS cross-reacted with the highly homologous pro-
tein ExoT (60), while that produced against the reduced-de-
natured form of ExoS favored specific reactivity with ExoS.
The differential intensities of the ExoS banding patterns of the
two antisera are consistent with their recognition of different
epitopes on ExoS. Immunoblot analyses of cell extracts of the
soil isolates found relative levels of ExoS to closely correspond
to those observed in culture supernatants (Fig. 2B). This indi-
cates that differences in ExoS production by these isolates
occurred at the level of gene expression rather than secretion.
Quantification of ExoS ADPRT activity in culture superna-
tants of soil and clinical isolates. To further compare the
properties of ExoS produced among soil and clinical isolates,
ExoS ADPRT activity was quantified in culture supernatants
of the strains grown, processed, and assayed for ADPRT en-
zymatic activity in parallel, under identical conditions (Fig. 3A
and B). As shown in Fig. 3A, differences were observed in the
levels of ExoS ADPRT activity among the soil isolates when
FIG. 1. ExoS ADPRT activity in culture supernatants of soil iso-
lates. The eight CCU soil isolates, indicated by the respective desig-
nations C1 to C6, C8, and C9, were cultured under ExoS induction
conditions for 18 h, and 10 ml of culture supernatant was assayed for
ExoS ADPRT activity. The results are expressed as the femtomoles of
ADP-ribose transferred per minute. The mean and standard error
(SE) of assays performed in duplicate from cultures grown and ana-
lyzed in parallel in three independent studies are represented.
FIG. 2. Immunoblot analyses of ExoS produced by soil and clinical
isolates. (A) Equal volumes (4 ml) of culture supernatants from soil
and clinical isolates grown in parallel under ExoS induction conditions
were resolved by SDS-PAGE on 7.5% polyacrylamide gels and immu-
noblotted with antisera produced against the native (upper blot) or the
reduced-denatured form of ExoS (lower blot). (B) Cell extracts (4 ml
of a twofold concentrate) were resolved as described above and im-
munoblotted with antisera produced against the native form of ExoS.
ExoS proteins were detected using peroxidase-conjugated goat anti-rat
IgG and ECL. The blots are representative of one of three indepen-
dent studies performed. Std represents an ExoS or ExoT standard,
previously quantified to have 20 ng of ExoS. Supernatants from CCU
isolates are labeled C1 to C6, C8, and C9, and the clinical isolates are
PAO1 (lane 01), 388 (lane 88), and DG1 (DG).
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serial dilutions of culture supernatants were assayed for activ-
ity. The highest levels of ExoS ADPRT activity were detected
in culture supernatants of strains CCU2 and CCU6, with the
lowest levels of activity produced by strains CCU4, CCU8, and
CCU1. ExoS ADPRT activity of each isolate was quantified
relative to the slope of the dilution curve within the linear
range of the assay (see Fig. 4 and 5). The results from these
studies are consistent with immunoblot analyses in supporting
that differences exist in the amount of ExoS being produced by
soil isolates.
More notable in comparisons of Fig. 3A and B were the
general lower levels of ExoS production detected in culture
supernatants of clinical isolates than in soil isolates. Strain
DG1 showed the highest level of ExoS ADPRT activity among
these clinical isolates, most closely approaching that of the soil
isolates. Lower levels of ExoS ADPRT activity were detected
in supernatants of strain 388, the prototype ExoS-producing
strain and its 388 DT (non-ExoT-producing) derivative strain
(60), the FRD1 and FRD2 related strains, and still lower levels
were detected in strain PA01 supernatants, the latter previ-
ously recognized as a low-ExoS-producing strain (14). Baseline
levels of ExoS ADPRT activity (;2 fmol min21 ml21) were
detected in culture supernatants of strain PA103, which pro-
duces high levels of the ADP-ribosylating toxin ETA but lacks
the exoS structural gene (11), confirming the specificity of the
ExoS ADPRT assay for ExoS. Similarly, baseline levels of
ExoS ADPRT activity (;0.4 fmol min21 ml21) were detected
in supernatants of strain 388DS, a derivative of strain 388 that
lacks the exoS structural gene (33).
To examine whether the differences detected in ExoS pro-
duction by soil isolates and clinical isolates would be evident in
soil isolates from a more distant geographical region and in
other clinical isolates, a second study was performed in which
two additional soil isolates, U1 and U3, and the clinical isolates
WR5, DO62, DO249, and PAK were cultured and assayed in
parallel for ExoS production (Fig. 3C). Soil isolate CCU2 was
cultured and assayed in these studies as an internal culture
control, and ADPRT results were normalized to those of pre-
vious studies using an internal ADPRT assay control. Again,
these analyses found the soil isolates to produce higher levels
of ExoS ADPRT than the clinical isolates, with strains WR5
and DO62 producing baseline levels of ExoS ADPRT activity.
Statistical analyses of ExoS ADPRT activity in culture super-
natants of the 10 soil and 9 clinical isolates shown in Fig. 3
found the soil isolates to produce significantly higher levels of
ADPRT activity than the clinical isolates (P 5 0.002), based on
Student t test analysis, with the mean production levels of ExoS
ADPRT activity of soil and clinical isolates being 209.1 6 36.9
and 48.9 6 24.8 fmol min21 ml21, respectively.
Comparison of ExoS production with other bacterial culture
characteristics. To evaluate how bacterial growth rates and
levels of protein secretion contributed to differences in ExoS
production by soil and clinical isolates, bacterial culture den-
sities and culture supernatant protein concentrations were
FIG. 3. Quantification of ExoS ADPRT activity in culture supernatants of soil and clinical isolates. Serial dilutions of culture supernatants from
the indicated soil isolates (A) and clinical isolates (B) were assayed for ADPRT activity, and the mean values of analyses performed in parallel
in two independent studies are represented. (C) ExoS ADPRT activities of soil isolates from a different geographical site and of additional clinical
isolates were compared in a second independent study in cultures grown and assayed for ADPRT activity in parallel. Strain CCU2 was included
in these studies as an internal culture control, and ADPRT results were normalized to those of panels A and B using an internal ADPRT assay
control. The results are expressed as femtomoles of ADP-ribose transferred per minute, and values obtained in the linear range of the assay were
used to quantify ExoS ADPRT of the individual isolates. Soil isolates are strains CCU1 to CCU6, CCU8, and CCU9 (C1 to C6, C8, and C9), U1,
and U3. Clinical isolates are strains 388 (curve 88), DG1 (DG), PAO1 (O1), FRD1 (F1), FRD2 (F2), PA103 (103) 388DT (DT), 388DS (DS), DO62
(curve 62), DO249 (curve 249), WR5 (WR), and PAK.
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compared with the ExoS ADPRT activity of the isolates. Rep-
resentative comparisons of these parameters in high- and low-
ExoS-producing soil and clinical isolates are shown in Fig. 4.
Calculations of ExoS ADPRT activity relative to protein levels
in culture supernatants were found to parallel the rates of
ExoS production in general, with the exception of strain 388.
Only low levels of protein were secreted by strain 388, making
the ratio of ExoS ADPRT activity to total supernatant protein
high. No correlations were detected between bacterial growth
rates or levels of secreted proteins and the production of ExoS
in these analyses (r 5 0.386 to 0.690) based on linear regression
analyses. The data support the idea that ExoS production is
regulated independently of bacterial growth rate or levels of
protein secretion when bacteria are grown in ExoS induction
medium.
To assess whether functional differences might exist in ExoS
secreted by the different strains, the relative specific activity of
ExoS in culture supernatants of soil and clinical isolates was
calculated. The specific activity of ExoS was quantified as the
ratio of ExoS ADPRT activity relative to the concentration of
ExoS immunoreactive protein, using densitometry analyses of
immunoblots probed with antisera to both the native and de-
natured forms of ExoS. Both antisera were used in ExoS quan-
tification to help alleviate bias in detection due to antibody
specificity. As shown in Fig. 5, the calculated specific activity of
ExoS produced by the soil isolates was, in general, higher than
that of clinical isolates, indicating that ExoS produced by soil
isolates was functionally more active. The exceptions to this
were CCU1, which lacked detectable ExoS production, and
ExoS produced by CCU4, which had a lower specific activity,
one closer to that of the clinical isolates.
Amplification of the exoS structural gene from soil isolates.
Differences observed in the immunoreactivity and specific ac-
tivity of ExoS produced among soil and clinical isolates sug-
gested that variation might exist in the exoS structural gene
sequence of P. aeruginosa within these two habitats. The exoS
genes of two P. aeruginosa clinical isolates, strains 388 and
PAO1, have previously been determined and were found to
differ by only one amino acid residue, the former having a
valine and the latter having a methionine at residue 62 (15, 35).
FIG. 4. Comparison of ExoS production with bacterial culture characteristics. Culture supernatant protein concentrations and bacterial growth
rates were compared with ExoS protein and ExoS ADPRT activity of representative high- and low-ExoS-producing soil and clinical isolates.
Secreted proteins in culture supernatants were compared and quantified based on an analysis of 10 ml of culture resolved by SDS–10% PAGE gels
and stained with Coomassie blue. Bacterial growth rates were related to the OD590 of cultures after growth in TSBD-N medium for 18 h. ExoS
protein concentrations were determined based on densitometry analysis of ExoS immunoblots of culture supernatants, performed as described in
the legend to Fig. 2, and probed with antisera against both the native and reduced-denatured forms of ExoS. ExoS ADPRT activity was quantified
as described in the legend to Fig. 3. The relative ratio of ExoS ADPRT activity to the concentration of total secreted protein for each isolate is
indicated. Strains are labeled as in Fig. 3, and the approximate mobilities of ExoT and ExoS are indicated by arrows.
FIG. 5. Specific ADPRT activity of ExoS produced by soil and
clinical isolates. The specific activity of ExoS in culture supernatants of
soil and clinical isolates was calculated based on the ratio of quantified
levels of ExoS ADPRT activity to ExoS protein concentrations, deter-
mined by immunoblot analyses, and related to an ExoS standard. The
specific activity is expressed as femtomoles of ADP-ribose transferred
per minute per nanogram of ExoS protein in the culture supernatants.
The results represent the mean and SE of two independent studies.
Soil and clinical isolates are labeled as in Fig. 3.
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A valine residue was, however, detected at position 62 in the
exoS gene in the PAO1 genome sequence (56) (GenBank ac-
cession number AE004801). Since the degree of conservation
of the exoS structural gene sequence between clinical and en-
vironmental P. aeruginosa isolates has not been previously ex-
amined, the complete nucleotide sequence of exoS from soil
isolates and additional clinical isolates was determined from
the respective PCR products.
Initial PCRs using primer set 1 allowed amplification of the
appropriate sized product from some but not all of the CCU
soil isolates (Fig. 6A). Primer set 2 amplified ExoS from all
isolates (Fig. 6B). The two primer sets differed in that primer
set 1 included shorter regions of hybridization, which defined
the beginning and end of the exoS gene and resulted in the
amplification of a second product. PCR products generated
from primer set 2 were used to determine the exoS gene se-
quences of soil and clinical isolates examined this study.
Comparison of nucleotide sequences of soil and clinical
isolates. The nucleotide sequences of the exoS genes deter-
mined from PCR products were compared, along with the exoS
gene sequence of strain PAO1 (15) (GenBank accession num-
ber X99471) to that of the prototype exoS gene of strain 388
(35) (GenBank accession number L27629). Analyses of the
exoS genes of soil isolates found that CCU1, which did not
produce a detectable ExoS product based on ADPRT activity
or immunoblot analyses, maintained an exoS structural gene
identical to that of strain 388, as did clinical isolate ATCC
27853. The exoS genes of CCU6 and CCU9 were also found to
be identical to each other. The exoS genes of CCU2, CCU6,
CCU9, CCU8, and DG1 had only synonymous (silent) nucle-
otide substitutions when compared to exoS of strain 388 (Table
1), while those of CCU3, CCU4, CCU5, U1, U3, FRD1, and
PAK had both synonymous and nonsynonymous substitutions
(Table 1). The nonsynonymous nucleotide substitutions re-
sulted in one to six amino acid changes in ExoS, depending on
the isolate (Table 1). Nucleotide changes were further classi-
fied into transitions (purine-to-purine or pyrimidine-to-pyrim-
idine shifts) and transversions (purine-to-pyrimidine or pyrim-
idine-to-purine shifts) (42, 43), with transitions being typically
more common than transversions. Table 2 summarizes the
ExoS sequence data of all strains, with respect to strain 388
ExoS. Sixty-one percent of nucleotide substitutions were syn-
onymous transitions in the third position, while 24% were
synonymous transversions in the third position. Fifteen percent
of the substitutions were nonsynonymous, with transitions oc-
curring at frequencies of 4 and 2% in the first and second
positions, respectively, and transversions occurring at frequen-
cies of 3, 4, and 2% in the first, second, and third positions,
respectively. Of interest in the comparison of the ExoS se-
quences is the clustering of synonymous substitutions in the
region corresponding to residues 52 to 83 and the clustering of
nonsynonymous substitutions in the region corresponding to
residues 157 to 191. Notable in the sequence comparisons
among soil and clinical isolates was the lack of nonsynonymous
substitutions in the region of ExoS predicted to form the
ADPRT active site cleft, thereby providing no direct explana-
tion for the increased specific activity detected in ExoS pro-
duced by soil isolates. What was noticed instead was the clus-
tering of amino acid substitutions in the region involved in
GAP function.
The evolution of the exoS genes of clinical and environmen-
tal isolates examined in this study was analyzed and is dis-
played as a tree showing three major clades (Fig. 7). Statistical
comparisons (two tailed) of the number of synonymous sub-
stitutions per synonymous site (dS) and the number of nonsyn-
onymous substitutions per nonsynonymous site (dN) were per-
formed to determine whether the exoS gene was under positive
selection, favoring amino acid replacement (dN . dS), or under
purifying selection, favoring amino acid stability (dS . dN).
ExoS was analyzed in this manner relative to (i) the entire exoS
gene, encoding amino acid residues 1 to 453; (ii) the N-termi-
nal domain, residues 1 to 234; (iii) the C-terminal domain,
residues 235 to 453; (iv) the type III signal sequence within
residues 1 to 9 (61); (v) the aggregation region, residues 1 to
99, predicted to interact with the chaperone, Orf1 (13, 30); (vi)
the GAP homology region, defined by residues 107 to 191; and
(vii) the ADPRT active site cleft, defined by residues 316 to
403. When all ExoS sequences were compared, dS was signif-
icantly greater than dN for the entire exoS gene (P , 0.001), its
N-terminal and C-terminal domains (P , 0.01), and within the
N-terminal domain, the aggregation region (P , 0.05), indi-
cating a strong purifying selection for ExoS generally and these
regions specifically (Table 3). Similar results were obtained
when ExoS sequences of the environmental and clinical iso-
lates were compared (not shown).
When the most divergent exoS genes, those of CCU4 and
PAK, were compared with all the other exoS genes, dS was
again significantly greater than dN for the entire exoS gene
(P , 0.01), a finding indicative of purifying selection (Table 3).
However, within the GAP region of ExoS of CCU4 and PAK,
which includes the nonsynonymous substitutions at residues
157, 159, and 162 in ExoS of CCU4, dN was greater than dS,
albeit not statistically significantly so (P . 0.05). To further test
the hypothesis of positive selection of the GAP domain in the
evolution of CCU4 and PAK, the method of Zhang et al. (64)
was used to estimate the rates of synonymous (bS) and non-
synonymous (bN) substitutions along the branches of the ExoS
tree leading to CCU4 and PAK. This analysis showed a signif-
icant positive selection of GAP (P , 0.05) along the branch
leading to CCU4 (bN 5 0.1616 6 0.00910; bS 5 0.0 6 0.0)
using a one-tailed Z test with infinite degrees of freedom. The
FIG. 6. Amplification of exoS structural genes from P. aeruginosa
soil and clinical isolates. The exoS gene was amplified from the
genomic DNA of the indicated bacterial strains using primer set 1 (A)
or primer set 2 (B) (see Materials and Methods). Products were re-
solved on 1% agarose gels. “L” indicates the DNA ladder, the CCU
soil isolates are numbered 1 to 6, 8, and 9, as indicated, and clinical
strains 388 (lane 88) and DG1 (DG) are labeled.
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same analyses detected no positive selection of GAP along any
other branch, and there was no positive selection of either the
aggregation domain or the ADPRT domain along any branch
in the ExoS tree. While positive selection indicates that a
protein sequence is still under selection pressure to change, it
does not indicate the direction of change (i.e., indicating gain
or loss of a particular function). The data support the notion
that while the ADPRT domain is genetically stable, changes in
the GAP region are being favored under certain conditions.
This in turn suggests that the evolution of the ADPRT domain
preceded the GAP region and that the GAP domain provides
an additional adaptive advantage to P. aeruginosa.
A third analysis was performed comparing the ExoT amino
acid sequence of strain 388 (60) (GenBank accession number
L46800), which is highly homologous to ExoS, with all ExoS
sequences, to gain further understanding of the evolutionary
relationship between these two proteins. The comparison re-
vealed strong purifying selection (dS . dN) for ExoT and
functional regions within ExoT (Table 3). A tree constructed
based on the ExoT protein sequence and all ExoS protein
sequences shows the distant divergence of ExoT from ExoS,
relative to the variation observed in ExoS sequences (Fig. 8).
The tree also shows strong support (83% of the bootstrap
TABLE 2. Type of nucleotide substitution for exoS genes of P. aeruginosa environmental and
clinical isolates compared to exoS gene of strain 388a
Amino acid
location
Codon
from 388 Amino acid
Mutated
codon
Resulting
amino acid
Type of mutation
Type of nucleotide
substitution Syn or Nonsyn
b Codon
position
46 GAC Asp GAG Glu Transversion Nonsyn 3rd
52 GGG Gly GGT Transversion Syn 3rd
52 GGG Gly GGA Transition Syn 3rd
58 GGC Gly GGT Transition Syn 3rd
60 GCG Ala GCA Transition Syn 3rd
62 GTG Val ATG Met Transition Nonsyn 1st
64 CCG Pro CCC Transversion Syn 3rd
74 AAA Lys AAG Transition Syn 3rd
83 GGC Gly GGG Transversion Syn 3rd
121 AGC Ser AAC Asn Transition Nonsyn 2nd
130 CTG Leu TTG Transition Syn 1st
157 GCC Ala TCC Ser Transversion Nonsyn 1st
159 AGC Ser AAC Asn Transition Nonsyn 2nd
160 CAG Gln CAA Transition Syn 3rd
162 GAG Glu AAG Lys Transition Nonsyn 1st
170 CGC Arg TGC Cys Transition Nonsyn 1st
191 GCG Ala TCG Ser Transversion Nonsyn 1st
212 CAG Gln CAA Transition Syn 3rd
221 CGC Arg CGT Transition Syn 3rd
266 GTG Val ATG Met Transition Nonsyn 1st
288 CAG Gln CAA Transition Syn 3rd
289 GAG Glu GAA Transition Syn 3rd
303 GCG Ala GCC Transversion Syn 3rd
310 CAG Gln CAA Transition Syn 3rd
329 GCA Ala GCC Transversion Syn 3rd
329 GCA Ala GCG Transition Syn 3rd
387 GAA Glu GAG Transition Syn 3rd
406 GTT Val GTC Transition Syn 3rd
415 CAG Gln CTG Leu Transversion Nonsyn 2nd
434 CGT Arg CCT Pro Transversion Nonsyn 2nd
436 GGC Gly GGT Transition Syn 3rd
448 CGC Arg CGT Transition Syn 3rd
450 CTT Leu CTC Transition Syn 3rd
a Data from the previously published sequences of strains 388 (35) and PAO1 (15) are incorporated into this table.
b Nonsyn and Syn, nonsynonymous and synonymous, respectively.
FIG. 7. Evolutionary relationship of exoS nucleotide sequences.
The exoS tree was constructed using the neighbor-joining method (52)
on Jukes-Cantor corrected nucleotide distances (28). The numbers on
the tree are the percentages of 1,000 bootstrap pseudo-replicates sup-
porting internal branches.
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samples) for the cluster of all ExoS proteins, excluding CCU4
and PAK, suggesting an early divergence of the latter among
ExoS proteins. The purifying selection of ExoT and ExoS is
further depicted in Fig. 8 (inset), which shows the distribution
of nonsynonymous substitutions throughout ExoT and ExoS
relative to strain 388 ExoS. The data support that during the
evolutionary divergence of ExoS and ExoT, both proteins, and
their respective functional regions, have undergone purifying
selection. This does not exclude the possibility of positive se-
lection associated with, or occurring shortly after, the diver-
gence of these proteins.
DISCUSSION
The ubiquitous distribution of P. aeruginosa in nature and
clinical settings indicates a close link between the environmen-
tal organism and the opportunistic pathogen. ExoS is one of
multiple factors believed to contribute to the virulence of
P. aeruginosa as an opportunistic pathogen. While it has been
previously recognized that both environmental and clinical iso-
lates produce ExoS (26), the genetic and functional relation-
ship of ExoS produced in these two habitats has not been
explored. The purpose of our studies was to examine ExoS
produced by soil isolates and, through comparisons with clin-
ical isolates, to gain an understanding of the conservation of
the ExoS structural gene, as well as insight into the role of
ExoS in P. aeruginosa virulence and survival.
In a cursory survey of the soils in Horry and Georgetown
counties in South Carolina, P. aeruginosa was isolated from
16% of the samples, indicating that it is relatively common in
soils in this region. Examination of ExoS production by these
isolates found seven of eight strains to produce high levels of
ExoS ADPRT activity. Variations were, however, detected in
levels of ExoS cross-reactive protein among the isolates when
culture supernatants were examined by immunoblot analyses.
These variations were later confirmed in ADPRT activity as-
says when serial dilutions of culture supernatants were assayed
for enzymatic activity and concentrations of ExoS ADPRT
activity were determined within the linear range of the dilution
curve. Of interest in comparisons of ExoS production of P.
aeruginosa soil and clinical isolates were the overall higher
levels of ExoS ADPRT activity produced by soil isolates. This
difference was apparent in our initial comparison of eight soil
and five clinical isolates and then in a second study comparing
two soil isolates from a more distant geographical location and
four additional clinical isolates. Statistical analysis of ExoS
ADPRT activity of 10 soil and 9 clinical isolates found produc-
tion by soil isolates to be significantly greater than that of
clinical isolates (P 5 0.002). When ExoS production was re-
lated to bacterial growth rates or levels of protein secretion, no
significant correlations were detected, supporting the idea that
ExoS production was regulated independently of these culture
characteristics.
To gain further understanding of the structure-function re-
lationship of ExoS produced by the different P. aeruginosa
strains, the specific activity of ExoS in culture supernatants
(ADPRT activity per nanogram of ExoS protein) was calcu-
lated for individual isolates. Considerable variation was de-
tected in ExoS specific activity among the isolates, with soil
isolates in general producing ExoS with a higher ADPRT ac-
tivity than clinical isolates. When the exoS genes of soil and
clinical strains were sequenced to gain further understanding
of the molecular mechanism for the higher activity, no obvious
explanation based on amino acid substitutions was evident.
This points to the possibility that other factors produced by
P. aeruginosa and/or amino acid substitutions outside the
ADPRT domain may be modulating ExoS ADPRT activity.
There is precedence for the notion that ExoS function or
ADPRT activity may be enhanced by either bacterial or eu-
karyotic factors. A chaperone, Orf1, coordinately regulated
with ExoS production, facilitates the transport of ExoS from
the prokaryotic cell and hence increases secreted ExoS activity
(15, 62). Within the eukaryotic cell, the modulating effect of
the 14-3-3 protein cofactor is required for maximal ADPRT
activity (7, 16). The potential therefore remains for these
TABLE 3. Mean dS and dN per 100 sites as estimated from comparisons between ExoS sequences, between CCU4 plus
PAK and other ExoS sequences, and between ExoT and ExoS sequences
Comparison Domain Aminoacids
Mean
dS 6 SE
Mean
dN 6 SE
P a
Between ExoS sequences All 1–453 2.1 6 0.4 0.2 6 0.1 ,0.001
Type III signal 1–9 0.0 6 0.0 0.0 6 0.0 NS
Aggregation 1–99 3.9 6 1.6 0.2 6 0.1 ,0.05
GAP homology 107–191 0.5 6 0.4 0.5 6 0.2 NS
ADPRT homology 316–403 1.8 6 1.1 0.0 6 0.0 NS
Between CCU4 plus PAK and other
ExoS sequences
All 1–453 2.4 6 0.6 0.5 6 0.2 ,0.01
Type III signal 1–9 0.0 6 0.0 0.0 6 0.0 NS
Aggregation 1–99 4.1 6 1.8 0.5 6 0.5 NS
GAP homology 107–191 0.3 6 0.3 1.0 6 0.5 NS
ADPRT homology 316–403 1.9 6 1.3 0.0 6 0.0 NS
Between ExoT and ExoS sequencesb All 1–457 50.9 6 5.0 16.2 6 1.4 ,0.001
Type III signal 1–9 71.7 6 64.8 14.6 6 8.6 NS
Aggregation 1–102 56.1 6 11.5 16.9 6 3.0 ,0.01
GAP homology 110–194 46.4 6 10.4 14.4 6 3.0 ,0.01
ADPRT homology 319–407 38.4 6 9.4 14.4 6 2.9 ,0.05
a NS, not significant.
b Amino acid boundaries reflect the ExoT sequence.
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and/or other unidentified factors to act as inhibitors or poten-
tiators of the ExoS ADPRT activity and contribute to the
differences observed in activity in environmental and clinical
isolates. In this regard, we found that ExoS produced by soil
isolates, like clinical isolates, requires the 14-3-3 cofactor for
ADPRT activity, indicating that if an enhancing factor is pro-
duced by soil isolates, it cannot replace the activity of the
14-3-3 cofactor. Another factor that may influence ExoS activ-
ity in soil isolates is the highly homologous and coordinately
regulated protein ExoT. ExoT was detected in all of the soil
isolates examined in this study, based either on immunoblot
analyses or on PCR amplification of the ExoT structural gene
(unpublished observation). ExoS exists in a high-molecular-
weight complex with ExoT in culture supernatants (34) and,
while there has been speculation as to the potential competi-
tive or coordinated function of these two proteins, the specific
effect of ExoT on ExoS function remains unknown.
Notably, relative to the possibility that residues outside the
ADPRT domain might be able to modulate ADPRT activity is
the clustering of amino acid substitutions in the GAP region of
ExoS, sometimes in association with a decrease in ADPRT
activity. While relatively few amino acid substitutions were
detected in ExoS produced by soil and clinical isolates, 7 of the
15 substitutions resulting in amino acid changes occurred
within the GAP homology region of ExoS. CCU4, which had a
lower level of ExoS ADPRT activity than the other soil iso-
lates, had the greatest number of amino acid substitutions,
three of which were within the GAP region (Ala-157 to Ser,
Ser-159 to Asn, and Glu-162 to Lys). The ExoS of FRD1,
CCU3, U1, and U3 also had amino acid substitutions within
the GAP region (Ser-121 to Asn, Arg-170 to Cys, and Ala-191
to Ser, respectively). While it remains to be proven whether the
GAP region of ExoS is contributing to the differences in
ADPRT activity detected among the isolates, the increased
amino acid variation within this region identifies it as a candi-
date site for modulation of ExoS function.
Analysis of the sequence variability of the exoS genes of 10
soil and 5 clinical P. aeruginosa isolates, a group which includes
the two previously sequenced exoS genes of strains 388 and
PAO1, provided insight into the evolutionary relationship of
ExoS produced in these two settings. The inter-relatedness of
the ExoS proteins of the soil and clinical isolates is evident in
the interspersing of the exoS genes among the clades in the tree
shown in Fig. 7. While foci of silent or synonymous substitu-
FIG. 8. Evolutionary relationship of ExoS and ExoT protein sequences. The ExoS-ExoT tree was constructed using all ExoS protein sequences
and the strain 388 ExoT sequence (60) as described in the legend to Fig. 7, except that the neighbor-joining method was applied to amino acid
distances between sequences. (Inset) Nonsynonymous substitutions within ExoT and ExoS. The positions of nonsynonymous substitutions within
ExoS and ExoT, relative to ExoS of strain 388, are indicated by vertical lines within the linear map of the respective proteins, with the width of
each line reflecting the number of substituted amino acids. Predicted functional regions within ExoS and ExoT are labeled and shaded. Numbers
that define the amino acid boundaries of the type III signal sequence (S) and aggregation domain have been previously reported (61). The GAP
and ADPRT regions are defined based on homology with other GAP or ADPRT proteins. The positions of residues integral to GAP function
(R146 or R149 in ExoS and ExoT, respectively) (19, 32) and ADPRT activity in ExoS (E381) (37) and the homologous residue in ExoT (E385)
are marked by arrows.
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tions were detected in soil isolates relative to strain 388, nu-
cleotide substitutions at these sites in many instances were
identical to those found in the other clinical isolates. The
positioning of isolates producing either low or high levels of
ExoS ADPRT activity on the same branch further highlights
the lack of relationship between the exoS gene sequence and
the levels of ExoS production. The data as a whole are consis-
tent with the ExoS of clinical isolates representing a fairly
accurate cross section of that produced in environmental set-
tings. Comparisons of the variability of the ExoS protein se-
quences to the ExoT sequence also provided insight into the
relatively distant divergence of these two proteins. The evi-
dence of strong purifying selection for both ExoS and ExoT in
these analyses, and their respective functional domains, sup-
ports the idea that both proteins maintain a stable, indepen-
dent function within P. aeruginosa.
The increased rate of ExoS production and the prevalence
of the exoS structural gene in soil isolates imply the importance
of ExoS to survival of P. aeruginosa in the soil. These results
are consistent with early studies of ExoS that found a high
percentage of environmental isolates (91%) to produce ExoS
(26). Conversely, the decreased rate of ExoS production by
clinical isolates, as well as the reported absence of the exoS
structural gene from cytotoxic corneal isolates (11) or the lack
of ExoS secretion from CF isolates (9), indicates the possible
lesser importance of ExoS in certain clinical settlings. The
production of ExoS by clinical isolates, however, appears
somewhat related to the site of infection, as is evident from the
general higher levels of ExoS production in P. aeruginosa iso-
lated from wound and urinary tract infections (50). When ExoS
expression is examined relative to that of other type III effector
proteins, a preferred pattern of expression emerges among
P. aeruginosa strains. For example, the paired expression of
ExoU-ExoT or ExoS-ExoT has been noted in P. aeruginosa
clinical isolates in the absence of the paired expression of
ExoU-ExoS or the expression of ExoS, ExoT, and ExoU (10).
Although ExoU production was not examined in our studies,
ExoS and ExoT expression or genes were detected in all soil
isolates, favoring the paired expression of ExoS and ExoT in
the soil. No conclusion can be drawn from our studies, how-
ever, as to the relative efficiency of ExoS and ExoT production
by soil isolates, due to the method of detection of ExoT and the
bias of the antisera used in immunoblot analyses for ExoS. All
data obtained from these analyses, though, are consistent with
ExoS production being favored and upregulated in association
with P. aeruginosa growth in the soil.
Based on the high expression of ExoS in the soil and assum-
ing that the soil is the point of origin for P. aeruginosa, it can
be hypothesized that the evolution of ExoS occurred as a result
of a selection pressure within this environment. The require-
ment for a eukaryotic cofactor for ExoS ADPRT activity pre-
sumes that ExoS coevolved with eukaryotic organisms. P.
aeruginosa likely encounters a myriad of eukaryotic species in
the soil, including plant roots, free-living nematodes, protozoa,
and fungi. Possible relationships that might introduce selection
pressures in this environment are parasitic or commensal re-
lationships on plant roots, prey-predator relationships with
protozoa and nematodes, and competition for substrates with
fungi. As P. aeruginosa adapts to certain clinical settings, the
selection pressure for ExoS production appears to be lessened,
as indicated by decreased levels of ExoS production or the lack
of the structural gene, rather than alterations in the gene
sequence. While we can currently only speculate as to the
different advantages ExoS might offer P. aeruginosa in its in-
teraction with eukaryotes in the soil versus clinical environ-
ments, the cellular sensitivities to ExoS notably mimic the
opportunistic lifestyle of P. aeruginosa. For example, relative to
epithelial monolayers, confluent, polarized monolayers are re-
sistant to the effects of ExoS-producing P. aeruginosa, whereas
compromised or subconfluent monolayers are sensitive (12,
40). In addition, when ExoS is translocated into sensitive epi-
thelial or fibroblastic cell lines, a general inactivation of cell
function is recognized, rather than an immediate cytotoxic
effect (40, 48). Similarly, the type III-mediated translocation of
ExoS into macrophages has been reported to have little effect
on viability (6) but can inhibit bacterial uptake (15). Consistent
with the role of ExoS as an anti-invasive factor, both ExoS and
ExoT have recently been found to interfere with the uptake
of P. aeruginosa by epithelial cells and macrophages in an
ADPRT-independent manner (8, 18). In contrast to the above
cell types, the promyeloblastic HL-60 cell line appears to be
resistant to the effects of ExoS (E. A. Rucks, T. S. Vincent,
J. C. Olson, Abstr. 100th Gen. Meet. Am. Soc. Microbiol. 2000,
abstr. B-329, p. 116, 2000). Based on these findings, ExoS may
provide an advantage to P. aeruginosa survival in the soil
through its ADPRT-dependent inactivation of eukaryotes it
encounters and its ADPRT-independent interference with
bacterial uptake. Alternatively in clinical settings, while the
inactivation of host cell function and antiphagocytic properties
of ExoS might be predicted to aid in the infectious process, the
limited toxicity of ExoS, combined with its inefficient targeting
of cells of lymphoid origin, may favor the production of more
cytotoxic factors, such as ExoU and ETA, at certain sites of P.
aeruginosa infection. Where ExoS is likely to come into play in
the infectious process, however, is when P. aeruginosa encoun-
ters damaged epithelial tissue.
We conclude from these studies that ExoS is integral to the
survival of P. aeruginosa in the soil but is less so in some clinical
settings. In relating this finding to an understanding of the
origin and evolution of ExoS as a virulence factor, our data
suggest that ExoS existed prior to the evolutionary transition
from the soil organism to the human pathogen. This, in turn,
supports the view that the lower frequency of expression of
ExoS in certain clinical settings relates to the loss of the gene
or gene expression rather than to its limited acquisition.
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